


PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search PubMed for

1: Gene Ther 2001 Jul;8(13):987-98

Entrez PubMed



A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component.

Emiliusen L, Gough M, Bateman A, Ahmed A, Voellmy R, Chester J, Diaz RM, Harrington K, Vile R.

Molecular Medicine Program, Guggenheim 18, Mayo Clinic, Rochester, MN 55905, USA.

Transcriptional targeting of cytotoxic genes is an important way to control toxicity associated with gene transfer therapies, but supposedly, tissue-specific promoters are often either very weak and/or leaky. In addition, the phenotypic leakiness of such tissue-specific promoters is dependent upon the toxicity of the gene being used. Therefore, we devised a transcriptional feedback loop to restrict gene expression of very potent genes to melanoma cells. We screened different elements of the human tyrosinase promoter to find one which gave no detectable expression in non-melanoma cells but was active in melanoma cell lines. This weak, but highly tissue specific, element (Tyr-300) was then used as the basis for a transcriptional amplification feedback loop in which a consensus heat shock element (HSE) was cloned upstream of Tyr-300. The cytotoxic gene was cloned downstream of the HSE-Tyr-300 element along with a mutated form of the heat shock factor-1 (HSF-1) transcription factor, which no longer requires cellular stress to activate its trimerisation, nuclear localisation and transcriptional activation properties. Low levels of expression from Tyr-300 initiated expression of both the cytotoxic and the HSF-1 genes in melanoma cells. Gradual build up of HSF-1 amplified expression through binding to the HSE to give levels of cytotoxicity similar to that provided by a CMV promoter. However, no leakiness was observed in multiple non-melanoma cell lines tested. In addition to amplifying low levels of weak tissue-specific expression, the use of HSF-1 also leads to activation of endogenous stress-related genes such as hsp70. Induction of these genes, in the presence of cell killing by the cytotoxic gene, is a highly immunostimulatory event which enhances the antitumour vaccination effects of direct tumour cell destruction. Having demonstrated the compatibility of the component elements in plasmid form, we incorporated the feedback loop into a hybrid LTR-modified retroviral vector and confirmed that the system can be effective in the form of a viral vector. The format of the feedback loop described here could be exploited for any tissue type in which

Related Resources

a highly tissue-specific element can be identified but which is itself too weak to be effective therapeutically.

PMID: 11438833 [PubMed - indexed for MEDLINE]

Display	Abstract	▼	Show: 20	▼	Sort	▼	Send to	Text	▼
---------	----------	---	----------	---	------	---	---------	------	---


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

May 2 2003 16:34:23



PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Books
Search PubMed	<input checked="" type="checkbox"/> for					Go	Clear	
		Limits	Preview/Index	History	Clipboard	Details		
			Display	Abstract	Show: 20	Sort	Send to	Text

Entrez PubMed

1: Mol Med Today 1998 Feb;4(2):84-92

[Related Articles, Links](#)

[DISPLAY ARTICLE](#)
[FULL-TEXT ARTICLE](#)

Strategies for achieving multiple layers of selectivity in gene therapy.

Vile RG, Sunassee K, Diaz RM.

PubMed Services

Laboratory of Molecular Therapy, Hammersmith Hospital, London, UK.
r.vile@icrf.icnet.uk

Here we review the progress towards the development of targeted vectors for direct *in vivo* delivery in gene therapy. Currently, there are many separate approaches. These include: simple physical/anatomical localization of administration of the vector at the site where gene transfer is required; exploitation of natural tropisms of plasmid, viral and cellular vectors; and the use of molecular engineering to change the specificity of proteins and nucleic acids so that they specifically recognize target ligands expressed on/in the target cells. Unfortunately, each of these approaches is usually imperfect by itself. However, combinations of these strategies might produce vectors in which several layers of imperfect targeting give an overall level of specificity that can justify systemic delivery of vectors to treat human disease.

Related Resources

Publication Types:

- Review
- Review, Tutorial

PMID: 9547795 [PubMed - indexed for MEDLINE]

Display	Abstract	Show: 20	Sort	Send to	Text
---------	----------	----------	------	---------	------

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

May 2 2003 16:34:23

Set Name Query
side by side

DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; THES=ASSIGNEE;
PLUR=YES; OP=AND

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
<u>L12</u>	L11 same (promoter)	41	<u>L12</u>
<u>L11</u>	(vector or (nucleic adj acid)) same ((amplification) same (activator))	81	<u>L11</u>
<u>L10</u>	L2 and (HSE and HSF)	2	<u>L10</u>
<u>L9</u>	L2 and ((amplification) same (transcription adj activator))	0	<u>L9</u>
<u>L8</u>	L2 same ((amplification) and (transcription adj activator))	0	<u>L8</u>
<u>L7</u>	L2 same ((amplification) same (transcription adj activator))	0	<u>L7</u>
<u>L6</u>	L4 and (HSF)	9	<u>L6</u>
<u>L5</u>	L4 and (HSF-1)	0	<u>L5</u>
<u>L4</u>	L2 and (HSE or (heat adj shock))	959	<u>L4</u>
<u>L3</u>	L2 and (amplification adj promoter)	10	<u>L3</u>
<u>L2</u>	((tissue or cell or tumor or tumour) adj specific) adj promoter	4358	<u>L2</u>
<u>L1</u>	Vile-richard-G\$.in.	3	<u>L1</u>

END OF SEARCH HISTORY